The increased use of newer potent immunomodulatory therapies for multiple sclerosis (MS),
including natalizumab, fingolimod, and dimethyl fumarate, has expanded the patient …

OBJECTIVES John Cunningham virus (JCV) is a polyoma virus that infects humans, mainly
in childhood or adolescence, and presents no symptomatic manifestations. JCV can cause …

Background: Progressive multifocal leukoencephalopathy (PML) caused by the JC virus is
the main limitation to the use of disease modifying therapies for treatment of multiple …

Background and Purpose Neurological involvement in Behçet's disease [neuro-Behçet's
disease (NBD)] is uncommon, but it is worth investigating since it can cause substantial …

Background The anti-JCV antibody index is widely used to monitor multiple sclerosis (MS)
patients receiving natalizumab, as seroconversion is linked to an increased risk of …

Introduction Natalizumab (NTZ) can be associated with an opportunistic infection,
progressive multifocal leukoencephalopathy (PML), caused by John Cunningham virus …

The use of a highly-effective treatment for multiple sclerosis (MS) is associated with a severe
risk of developing complications, such as progressive multifocal leukoencephalopathy …

Background Natalizumab is a medication of choice for some patients with relapsing remitting
(RR) form of multiple sclerosis (MS). John Cunningham virus (JCV) antibody status is …

Objective The aim of this study was to evaluate the evolution of JCV index over time in
Natalizumab treated people with multiple sclerosis. Materials and Methods We …

Abstract Background Anti-JC virus (JCV) antibody testing has been used increasingly to
stratify multiple sclerosis (MS) patients into different disease modifying therapies. Objectives …